Perelman School of Medicine

FDA Designates Novartis-Penn Leukemia Treatment as ‘Breakthrough Therapy’

July 9, 2014

David Porter of the Perelman School of Medicine discusses working with Novartis on a new way to treat leukemia.

Study: Blood Test Might Help Identify Alzheimer’s Earlier

July 8, 2014

Jason Karlawish of the Perelman School of Medicine is quoted about questions that arise about the stigma that accompanies Alzheimer’s testing.

Article Source: Washington Post

The Moral Vision of the Reformicons

July 7, 2014

Jonathan Moreno of the Perelman School of Medicine and the School of Arts & Sciences contributes his thoughts on “reformicons.”

Article Source: Democracy Journal

Who Owns the Social Network?

July 1, 2014

Jonathan Moreno of the Perelman School of Medicine and the School of Arts & Sciences writes about social network analysis.

Article Source: Psychology Today

Study: Small Percentage of Hepatitis C Patients Got Through Past Treatments

July 8, 2014

Baligh Yehia of the Perelman School of Medicine comments on studying hepatitis C treatment in the U.S.

Penn Gets FDA ‘Breakthrough’ Designation for Experimental Cancer Therapy

July 7, 2014

Carl June of the Perelman School of Medicine is quoted about research on experimental leukemia therapy.

facebook twitter google print email
Media Contact:Evan Lerner | elerner@upenn.edu | 215-573-6604July 9, 2014

Penn to Lead $22.5 Million Project on Restoring Memory Loss

blurb: 
Penn scientists and physicians will conduct fundamental research on the brain with the aim of developing "neuroprosthetic" devices for treating memory loss due to disease or traumatic injury.

A team of scientists and physicians at the University of Pennsylvania will lead a four-year effort worth as much as $22.5 million to develop next-generation technologies to restore memory function in people who suffer from memory loss due to disease or traumatic injury.

facebook twitter google print email
Media Contact:Holly Auer | holly.auer@uphs.upenn.edu | 215-349-5659July 7, 2014

Penn's Personalized Cellular Therapy for Leukemia Receives FDA's Breakthrough Therapy Designation

A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration’s Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL).

Healing Found in Having Patients Relive Their Pain Over and Over

July 6, 2014

Edna Foa of the Perelman School of Medicine is featured for developing a therapy that requires patients to relive a horrific event to lessen its power.

Article Source: Philadelphia Inquirer

Former O-Care Adviser: Health Insurers Will Be ‘Dead’ by 2025

July 1, 2014

Ezekiel Emanuel of the Perelman School of Medicine and the Wharton School predicts massive changes in the traditional role of health insurers by 2025.

Article Source: The Hill